Harvard Business Review

MAY 26, 2014

Four dynamics are driving this new era of health care innovation: Finally, there is a financial incentive to innovate. billion in 2013, up 39% from 2012. While we are only in the early days of the open data movement, innovative uses of data will empower new approaches to improving outcomes.

Health Care 8

Health Care Venture Funding Entrepreneur Pharmaceuticals 8

Harvard Business Review

NOVEMBER 30, 2017

A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades. In some instances, the end results were firm closures and lost jobs. manufacturers are taking notice.

Supply Chain 8

Supply Chain McKinsey Incentives Bottom-up 8

Harvard Business Review

NOVEMBER 4, 2014

Take Sovaldi, launched by Gilead Sciences in late 2013 as a treatment for hepatitis C virus (HCV) infection and recently superseded by Gilead’s newest drug, Harvoni. To illustrate the problem, let’s start with an example from October 2013, when Express Scripts decided to exclude 46 drugs from its formulary. Health Innovation'

Cost 8

Cost Committee Insurance Health Care 8

Harvard Business Review

NOVEMBER 4, 2014

Take Sovaldi, launched by Gilead Sciences in late 2013 as a treatment for hepatitis C virus (HCV) infection and recently superseded by Gilead’s newest drug, Harvoni. To illustrate the problem, let’s start with an example from October 2013, when Express Scripts decided to exclude 46 drugs from its formulary. Health Innovation'

Cost 8

Cost Committee Insurance Health Care 8

Harvard Business Review

FEBRUARY 11, 2016

McKesson, the US-based pharmaceutical and health-care giant, benefits from external expertise as a strategic extension of its resources in areas such as business strategy and logistics support. ” Most managers would never dream of treating externals like internals. One of the main problems is decision making.

Agility 8

Agility Organization Resources Fixed Costs 8

Harvard Business Review

FEBRUARY 6, 2014

And that question is likely to be answered in the affirmative if the directors have managed to avoid the Peter Principle. Great at mid-level, the managers were not game-ready for the next level. Or consider managed-health care provider Humana’s decision in 2013 to recruit an outsider as its next chief executive.

CEO 8

CEO Bottom-up Strategic Fit Pharmaceuticals 8

Harvard Business Review

OCTOBER 11, 2013

Four years ago, Craig Hatkoff, co-founder of the Tribeca Film Festival, approached me about a brainstorm: an event recognizing and celebrating breakthrough innovators. When I suggested to Clayton Christensen that we partner with Hatkoff to create the Tribeca Disruptive Innovation Awards , Clay’s response was : I trust you Whitney.

Innovation 11

Innovation Christensen Decisionmaking CTO 11